Clarified strategies in terms of scope and prioritisation between studies
Shortened timelines for selecting higher value drug candidates
Lower risk in early development programs and optimisation of R&D costs
Higher project team autonomy in regulatory preclinical and clinical development
Enhanced chances for a much higher project valorisation
Years of experience
Clients
Studied molecules
Latest news

Le mot du président AFSSI
A découvrir... Joël Vacus, CEO de Drugabilis et président de l’AFSSI depuis 2019, fait le bilan de...
more news>
useful ressources
job offers/application
contact us